These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24346611)

  • 21. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study.
    Zhang J; Delzell E; Xie F; Baddley JW; Spettell C; McMahan RM; Fernandes J; Chen L; Winthrop K; Curtis JR
    Arthritis Res Ther; 2011; 13(5):R174. PubMed ID: 22024532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom.
    Smitten AL; Choi HK; Hochberg MC; Suissa S; Simon TA; Testa MA; Chan KA
    Arthritis Rheum; 2007 Dec; 57(8):1431-8. PubMed ID: 18050184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis.
    Sokka T; Pincus T
    Arthritis Rheum; 2003 Feb; 48(2):313-8. PubMed ID: 12571838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design characteristics of the Corrona Japan rheumatoid arthritis registry.
    Yamanaka H; Kishimoto M; Pappas DA; Greenberg JD; Kremer JM; Tanaka Y
    Mod Rheumatol; 2018 Jan; 28(1):95-100. PubMed ID: 28448195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.
    Kavanaugh A; Lee SJ; Curtis JR; Greenberg JD; Kremer JM; Soto L; Etzel CJ; Cox V; Yoshida K; Reed GW; Solomon DH
    Ann Rheum Dis; 2015 Jun; 74(6):1150-5. PubMed ID: 25471471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database.
    Sakai R; Kasai S; Hirano F; Harada S; Kihara M; Yokoyama W; Tsutsumino M; Nagasaka K; Koike R; Yamanaka H; Miyasaka N; Harigai M
    Int J Rheum Dis; 2018 Sep; 21(9):1670-1677. PubMed ID: 29667330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Do Patients With Moderate or High Disease Activity Escalate Rheumatoid Arthritis Therapy According to Treat-to-Target Principles? Results From the Rheumatology Informatics System for Effectiveness Registry of the American College of Rheumatology.
    Yun H; Chen L; Xie F; Patel H; Boytsov N; Zhang X; Curtis JR
    Arthritis Care Res (Hoboken); 2020 Feb; 72(2):166-175. PubMed ID: 31566905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.
    Zink A; Strangfeld A; Schneider M; Herzer P; Hierse F; Stoyanova-Scholz M; Wassenberg S; Kapelle A; Listing J
    Arthritis Rheum; 2006 Nov; 54(11):3399-407. PubMed ID: 17075823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year.
    Kay J; Morgacheva O; Messing SP; Kremer JM; Greenberg JD; Reed GW; Gravallese EM; Furst DE
    Arthritis Res Ther; 2014 Feb; 16(1):R40. PubMed ID: 24485007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
    Yun H; Xie F; Delzell E; Chen L; Levitan EB; Lewis JD; Saag KG; Beukelman T; Winthrop K; Baddley JW; Curtis JR
    Ann Rheum Dis; 2015 Jun; 74(6):1065-71. PubMed ID: 24608404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The CORRONA database.
    Kremer JM
    Autoimmun Rev; 2006 Jan; 5(1):46-54. PubMed ID: 16338211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study.
    Yoshida K; Radner H; Mjaavatten MD; Greenberg JD; Kavanaugh A; Kishimoto M; Matsui K; Okada M; Reed G; Saeki Y; Tohma S; Kremer J; Solomon DH
    J Rheumatol; 2015 Dec; 42(12):2238-46. PubMed ID: 26523025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease.
    Jin Y; Kang EH; Brill G; Desai RJ; Kim SC
    J Rheumatol; 2018 Aug; 45(9):1240-1248. PubMed ID: 29764964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries.
    Askling J; Berglind N; Franzen S; Frisell T; Garwood C; Greenberg JD; Ho M; Holmqvist M; Horne L; Inoue E; Michaud K; Nyberg F; Pappas DA; Reed G; Tanaka E; Tran TN; Verstappen SM; Yamanaka H; Wesby-van Swaay E; Symmons D
    Ann Rheum Dis; 2016 Oct; 75(10):1789-96. PubMed ID: 26621482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists.
    Kamal KM; Madhavan SS; Hornsby JA; Miller LA; Kavookjian J; Scott V
    Joint Bone Spine; 2006 Dec; 73(6):718-24. PubMed ID: 16997599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors.
    Segan J; Staples MP; March L; Lassere M; Chakravarty EF; Buchbinder R
    Intern Med J; 2015 Mar; 45(3):310-8. PubMed ID: 25565419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
    Clark W; Jobanputra P; Barton P; Burls A
    Health Technol Assess; 2004 May; 8(18):iii-iv, ix-x, 1-105. PubMed ID: 15130461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population.
    Yun H; Xie F; Delzell E; Chen L; Yang S; Saag KG; Joseph G; Harrison D; Curtis JR
    Br J Clin Pharmacol; 2015 Dec; 80(6):1447-57. PubMed ID: 26130274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
    Calabrese LH; Abud-Mendoza C; Lindsey SM; Lee SH; Tatulych S; Takiya L; Iikuni N; Soma K; Luo Z; Fleischmann R
    Arthritis Care Res (Hoboken); 2020 Mar; 72(3):353-359. PubMed ID: 31207152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.